78 related articles for article (PubMed ID: 17418069)
1. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
2. The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy.
Vesely S; Jarolim L; Duskova K; Schmidt M; Dusek P; Babjuk M
BMC Urol; 2014 Oct; 14():79. PubMed ID: 25277310
[TBL] [Abstract][Full Text] [Related]
3. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database.
Moreira DM; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Boffetta P; Freedland SJ
Cancer; 2014 Jan; 120(2):197-204. PubMed ID: 24127391
[TBL] [Abstract][Full Text] [Related]
4. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics.
Sood A; Zhang LT; Keeley J; Butaney M; Stricker M; Andrews JR; Grauer R; Peabody JO; Rogers CG; Menon M; Abdollah F
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):58-64. PubMed ID: 35794359
[TBL] [Abstract][Full Text] [Related]
5. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy.
Shah SR; Freedland SJ; Aronson WJ; Kane CJ; Presti JC; Amling CL; Terris MK
BJU Int; 2009 May; 103(9):1168-72. PubMed ID: 19298411
[TBL] [Abstract][Full Text] [Related]
6. The natural history of a delayed detectable PSA after radical prostatectomy.
Szymaniak JA; Washington SL; Cowan JE; Cooperberg MR; Lonergan PE; Nguyen HG; Meng MV; Carroll PR
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):759-764. PubMed ID: 36765111
[TBL] [Abstract][Full Text] [Related]
7. DNA Ploidy as a Potential Adjunct Prognostic Marker of Low-Risk Prostate Cancer Progression after Radical Prostatectomy.
Pukl M; George M; Javanmardi A; Carraro A; Korbelik J; White R; MacAulay C; Palcic B; Keyes M; Volavšek M; Guillaud M
Urol J; 2024 Mar; 21(2):80-86. PubMed ID: 37481706
[TBL] [Abstract][Full Text] [Related]
8. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Morgan TM; Lange PH; Porter MP; Lin DW; Ellis WJ; Gallaher IS; Vessella RL
Clin Cancer Res; 2009 Jan; 15(2):677-83. PubMed ID: 19147774
[TBL] [Abstract][Full Text] [Related]
9. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.
Blum DL; Koyama T; M'Koma AE; Iturregui JM; Martinez-Ferrer M; Uwamariya C; Smith JA; Clark PE; Bhowmick NA
Clin Cancer Res; 2008 Dec; 14(23):7790-7. PubMed ID: 19047106
[TBL] [Abstract][Full Text] [Related]
10. European Association of Urology biochemical recurrence risk groups after radical prostatectomy: External validation and identification of independent risk factors for progression and death.
Sopeña Sutil R; Vázquez-Martul D; De Pablos-Rodríguez P; Peña Vallejo E; Altez Fernández C; Gómez-Ferrer Lozano A; Téigell Tobar J; Rollón Prieto G; Coy García A; Ramírez Backhaus M; Chantada Abal V; Rodríguez Antolín A
Actas Urol Esp (Engl Ed); 2023 Sep; 47(7):422-429. PubMed ID: 36746348
[TBL] [Abstract][Full Text] [Related]
11. Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
Swanson GP; Lenz L; Stone S; Cohen T
Prostate; 2021 Mar; 81(4):261-267. PubMed ID: 33475174
[TBL] [Abstract][Full Text] [Related]
12. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.
Bjartell AS; Al-Ahmadie H; Serio AM; Eastham JA; Eggener SE; Fine SW; Udby L; Gerald WL; Vickers AJ; Lilja H; Reuter VE; Scardino PT
Clin Cancer Res; 2007 Jul; 13(14):4130-8. PubMed ID: 17634540
[TBL] [Abstract][Full Text] [Related]
13. PSA density of the lesion: a mathematical formula that uses clinical and pathological data to predict biochemical recurrence in prostate cancer patients.
Junqueira PHR; Santos GAD; Xavier M; Romão P; Reis S; Srougi M; Nahas WC; Passerotti CC
Rev Col Bras Cir; 2021; 48():e20212965. PubMed ID: 34644741
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.
Cui F; Qiu Y; Xu W; Zou C; Fan Y
BMC Cancer; 2024 Mar; 24(1):305. PubMed ID: 38448818
[TBL] [Abstract][Full Text] [Related]
15. SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death.
Song X; Ru M; Steinsnyder Z; Tkachuk K; Kopp RP; Sullivan J; Gümüş ZH; Offit K; Joseph V; Klein RJ
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1466-1472. PubMed ID: 35511739
[TBL] [Abstract][Full Text] [Related]
16. Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy.
Alyamani M; Michael P; Hettel D; Thomas L; Lundy SD; Berk M; Patel M; Li J; Rashidi H; McKenney JK; Klein EA; Sharifi N
J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37655657
[TBL] [Abstract][Full Text] [Related]
17. Association between Pre-Operative Total Prostate-Specific Antigen and Survivorship of Prostate Cancer following Radical Prostatectomy: A Systematic Review.
Okwor CJ; Okwor VC; Meka IA; Emedoh AE; Nweke M
Med Princ Pract; 2024; 33(2):102-111. PubMed ID: 38142683
[TBL] [Abstract][Full Text] [Related]
18. HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.
Timofte AD; Giuşcă SE; Lozneanu L; Manole MB; Prutianu I; Gafton B; Rusu A; Căruntu ID
Rom J Morphol Embryol; 2021; 62(1):41-52. PubMed ID: 34609407
[TBL] [Abstract][Full Text] [Related]
19. Editorial Comment to Validation of schedules for optimal PSA monitoring after radical prostatectomy.
Matsumoto K
Int J Urol; 2024 Apr; 31(4):408-409. PubMed ID: 38229417
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Discussing the Optimal Treatment Strategy Against Persistent PSA After Radical Prostatectomy.
Matsumoto K; Komori T; Oya M
Ann Surg Oncol; 2023 Oct; 30(11):6943-6944. PubMed ID: 37405665
[No Abstract] [Full Text] [Related]
[Next] [New Search]
